Entero Therapeutics, Inc. (NASDAQ:GRDX) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 43,189 shares, a drop of 41.2% from the May 31st total of 73,503 shares. Based on an average trading volume of 123,990 shares, the short-interest ratio is presently 0.3 days. Currently, 0.7% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Entero Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned approximately 1.45% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors own 12.30% of the company’s stock.

Entero Therapeutics Price Performance

GRDX remained flat at $4.40 during trading hours on Friday. The company had a trading volume of 42,197 shares, compared to its average volume of 79,962. The firm’s 50-day moving average is $4.36. Entero Therapeutics has a one year low of $1.08 and a one year high of $6.93. The stock has a market capitalization of $29.27 million, a price-to-earnings ratio of -2.34 and a beta of 1.81.

Entero Therapeutics (NASDAQ:GRDX) last released its earnings results on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The business had revenue of $0.04 million during the quarter.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.